Evidence map›Paper›PMID 42317548›Full record

ReviewBiophysical reviews2026

Precision by design: Surface plasmon resonance and the integration of biophysics in fragment-based drug discovery.

Todd W Pascarella, Jeremiah S Joseph, Jason M Newman, Júlio C Borges, Paulo R Dores-Silva

Abstract readReview
In one paragraph

Review in Biophysical reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Biophysical reviews · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Todd W PascarellaValenthos Biophysics, 1740 Robinson Ave, San Diego, CA 92103 USA.
Jeremiah S JosephOpilio LLC, 1838 Torre Lane, Chula Vista, CA 91915 USA.
Jason M NewmanValenthos Biophysics, 1740 Robinson Ave, San Diego, CA 92103 USA.
Júlio C BorgesSão Carlos Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
Paulo R Dores-SilvaFerring Ventures Inc, 4245 Sorrento Valley Blvd, San Diego, CA 92121 USA.ORCID 0000-0001-8656-7769

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surface plasmon resonance (SPR) is a widely adopted and highly informative biophysical technique in fragment-based drug discovery, enabling the detection and characterization of weak and transient molecular interactions that initiate the progression from fragments to lead compounds. Owing to its sensitivity, low sample consumption, and compatibility with both direct-binding and functional assay formats, SPR plays a central role within integrated fragment discovery workflows, supporting affinity estimation, hit validation, and mechanistic interrogation when applied with appropriate experimental design. Recent advances in sensor-chip chemistries, buffer and solvent optimization, clean-screening strategies, and high-throughput instrumentation have further enhanced the robustness and reliability of SPR-based fragment assays. When combined with complementary biophysical and structural approaches, including thermal shift analysis, calorimetry, mass spectrometry, thermophoresis, NMR spectroscopy, X-ray crystallography, and cryo-electron microscopy, SPR contributes to a multidimensional validation framework that enables informed hit triage, structural interpretation, and structure-guided optimization. This review provides a practical guide to the use of SPR in fragment-based discovery, covering conceptual principles, experimental design, data analysis strategies, and best practices for minimizing artifacts and improving data quality. Beyond technical considerations, SPR illustrates a broader principle of molecular discovery: even weak interactions, when measured rigorously and interpreted in context, can yield insights that guide the transformation of fragment hits into biologically meaningful and therapeutically relevant molecules.

Indexed as

BiophysicsFBDDScreeningSPRStructural biology

Identifiers

PMID42317548
PMCPMC13272721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.